Flagship Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Flagship Biosciences, Inc. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include SPATIALPLEX, TISSUEINSIGHT, and FLAGSHIP BIOSCIENCES. The owner is based in Westminster, CO.
7575 W. 103rd
Suite 102
Westminster, CO 80021
Showing of trademarks Trademarks
Trademark Classifications
Flagship Biosciences, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Flagship Biosciences, Inc. have?
Flagship Biosciences, Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 6 abandoned, 2 cancelled.
What trademark classes does Flagship Biosciences, Inc. file in?
Flagship Biosciences, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Flagship Biosciences, Inc.'s most well-known trademarks?
Flagship Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as SPATIALPLEX, TISSUEINSIGHT, and FLAGSHIP BIOSCIENCES. These are among 3 currently registered trademarks in the portfolio.
What is Flagship Biosciences, Inc.'s trademark registration success rate?
Flagship Biosciences, Inc. has a 27% trademark registration rate, with 3 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.